Recently, the Zhejiang Provincial Science and Technology Department announced the list of the first batch of "Cutting-edge" and "Leading Eagle" research and development projects for 2023. The project "Phase I/II clinical research of a novel IL-2 fusion protein targeting PD-1 for the treatment of advanced malignant tumors" submitted by Novatim Immune Therapeutics (Zhejiang) Co., Ltd.(hereinafter referred to as "Novatim") was approved for funding. This is the only project among the first batch of 2023 projects that was awarded funding by a Zhejiang private enterprise in the field of tumor immunotherapy.
Dr. Wu Guoxiang, the founder and project leader of the company, introduced that this is the first domestically-developed, targeted PD-1 type new IL-2 fusion protein independently researched by Novatim. It was approved by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) in August this year to start clinical trials. It is expected to complete the first patient enrollment at the Chinese People's Liberation Army General Hospital by the end of November this year. Its unique design concept has played the role of a new-generation agonist. This product is ranked second in the global research progress in the same field, only after Roche. It has obtained a number of international and domestic patents.
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. was established in 2018. It is a biopharmaceutical technology enterprise specializing in the research and clinical application of innovative drugs for tumor immunotherapy. It wholly owns
Shanghai Tinova Immune Therapeutics Co., Ltd. (focused on the research and clinical application of the new generation of CAR-T). Based on clinical needs and its focus on tumor immunotherapy, the company has established R&D platforms for dual-function antibodies, ADC, solid tumor CAR-T, and hematological tumor CAR-T, and has developed more than 8 FIC/BIC products.
